United Therapeutics Corporation
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $1.60B | $1.47B | $1.29B | $1.12B | $916.1M | $743.2M | $592.9M |
| Cost of Revenue | $105.7M | $72.7M | $69.0M | $125.9M | $131.1M | $119.3M | $88.9M | $67.7M |
| Gross Profit | $1.62B | $1.53B | $1.40B | $1.15B | $975.8M | $786.8M | $652.2M | $524.0M |
| Gross Margin | 93.9% | 95.5% | 95.3% | 89.5% | 87.4% | 85.9% | 87.8% | 88.4% |
| Operating Expenses | ||||||||
| Research & Development | $264.6M | $147.6M | $245.1M | $242.5M | $299.3M | $173.4M | $180.0M | $165.3M |
| SG&A Expense | $330.1M | $316.8M | $452.7M | $381.3M | $394.0M | $201.7M | $156.5M | $188.6M |
| Operating Income | $814.9M | $1.06B | $699.0M | $538.8M | $292.5M | $421.6M | $317.8M | $171.3M |
| Operating Margin | 47.2% | 66.4% | 47.7% | 41.8% | 26.2% | 46.0% | 42.8% | 28.9% |
| Interest Expense | $9.0M | $3.9M | $4.7M | $17.6M | $18.1M | $16.6M | $21.4M | $19.7M |
| Pretax Income | $769.5M | $1.06B | $1.04B | $525.2M | $278.9M | $440.7M | $299.1M | $155.2M |
| Income Tax Expense | $351.6M | $346.5M | $392.8M | $185.1M | $104.3M | $136.2M | $81.9M | $43.9M |
| Net Income | $417.9M | $713.7M | $651.6M | $340.1M | $174.6M | $304.4M | $217.9M | $105.9M |
| Net Margin | 24.2% | 44.6% | 44.5% | 26.4% | 15.6% | 33.2% | 29.3% | 17.9% |
| EPS (Basic) | $9.50 | $16.29 | $14.17 | $7.06 | $3.49 | $5.84 | $3.81 | $1.89 |
| EPS (Diluted) | $9.31 | $15.25 | $12.72 | $6.28 | $3.28 | $5.71 | $3.67 | $1.78 |
| Shares Outstanding (Basic) | 44.0M | 43.8M | 46.0M | 48.2M | 50.1M | 52.1M | 57.2M | 56.1M |
| Shares Outstanding (Diluted) | 44.9M | 46.8M | 51.2M | 54.2M | 53.2M | 53.3M | 59.4M | 59.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |